Volume 8.18 | May 10

Mesenchymal Cell News 8.18 May 10, 2016
Mesenchymal Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MESCN on Twitter
Secreted Microvesicular miR-31 Inhibits Osteogenic Differentiation of Mesenchymal Stem Cells
Scientists found that circulating microvesicles impact on the osteogenic differentiation capacity of mesenchymal stem cells in a donor-age-dependent way. While searching for factors mediating the inhibitory effect of elderly derived microvesicles on osteogenesis, they identified miR-31 as a crucial component. [Aging Cell] Abstract
Roles for mesenchymal stem cells as medicinal signaling cells. Request your FREE copy today.
PUBLICATIONS (Ranked by impact factor of the journal)

Ginsenoside Rg1 Promotes Osteogenic Differentiation of rBMSCs and Healing of Rat Tibial Fractures through Regulation of GR-Dependent BMP-2/SMAD Signaling
Researchers investigated the effect of Rg1 on osteogenic differentiation of cultured bone marrow mesenchymal stem cells (BMSCs) and related mechanisms and on the fracture healing in a fracture model. [Sci Rep] Full Article

Autonomous Magnetic Labelling of Functional Mesenchymal Stem Cells for Improved Traceability and Spatial Control in Cell Therapy Applications
The authors demonstrated efficient live mesenchymal stem cell (MSC) labelling using silica-coated magnetic particles, which enables 3D tracking and guidance of stem cells. A procedure developed for the efficient and unassisted particle uptake was shown to support MSC viability and integrity, while surface marker expression and MSC differentiation capability were also maintained. [J Tissue Eng Regen Med] Full Article

TGF-β3-Induced miR-494 Inhibits Macrophage Polarization via Suppressing PGE2 Secretion in Mesenchymal Stem Cells
Researchers found that miR-494 over-expressed decidual mesenchymal stem cells inhibit M2 macrophages polarization and this inhibitory effect is mediated by miR-494-reduced PGE2 secretion. [FEBS Lett] Abstract | Full Article

Establishment of a Cytocompatible Cell-Free Intervertebral Disc Matrix for Chondrogenesis with Human Bone Marrow-Derived Mesenchymal Stromal Cells
Scientists prepared a cell-free decellularized human intervertebral disc (IVD) scaffold and compared neotissue formation in response to recellularization with human IVD cells or human bone marrow-derived mesenchymal stromal cells. [Cells Tissues Organs] Full Article

Osteoblastic Differentiation of Bone Marrow Mesenchymal Stromal Cells in Bruck Syndrome
Mononuclear cells obtained from the bone marrow of BS, OI patients and healthy donors were cultured and osteogenic differentiation was induced. The gene expression of osteoblast specific markers were also evaluated during the osteoblastic differentiation of mesenchymal stem cells by qRT-PCR using an ABI7500 Sequence Detection System. [BMC Med Genet] Full Article


E-Prostanoid 2 Receptor Overexpression Promoted Mesenchymal Stem Cell Attenuated Lung Injury
Near-infrared imaging and immunofluorescence both showed that compared with mesenchymal stem cells (MSCs)-GFP, MSCs-E-prostanoid 2 (EP2) significantly enhanced MSC homing to injured lung tissue. In vivo experimental results suggested that compared with the MSCs-GFP, the MSCs-EP2 further reduced LPS-induced pulmonary vascular permeability, as reflected by reduced levels of Evans blue in lung parenchymal homogenates. [Hum Gene Ther] Abstract

Preclinical Biosafety Evaluation of Genetically Modified Human Adipose Tissue–Derived Mesenchymal Stem Cells for Clinical Applications to Brainstem Glioma
Scientists injected a stereotactically low, medium, or high dose of human adipose tissue-derived mesenchymal stem cell secreted form of tumor necrosis factor-related apoptosis-inducing ligand (hAT-MSC.sTRAIL) into the brainstems of immune-deficient mice reflecting the plan of a future clinical trial. Local toxicity, systemic toxicity, secondary tumor formation, and bio-distribution of hAT-MSC.sTRAIL were investigated. [Stem Cells Dev] Abstract

Chm-1 Gene-Modified Bone Marrow Mesenchymal Stem Cells Maintain the Chondrogenic Phenotype of Tissue-Engineered Cartilage
The authors compared chondromodulin-1 (Chm-1) expression between chondrocytes and mesenchymal stem cells (MSCs). They found that chondrocytes expressed a high level of Chm-1. They then adenovirally transduced MSCs with Chm-1 and applied modified cells to engineer cartilage in vivo. [Stem Cell Res Ther] Full Article

Take the Guesswork Out of Finding the Right Antibody. 25% Off Your First Order With the Purchase of Another Product
Mesenchymal Stem Cell Subpopulations: Phenotype, Property and Therapeutic Potential
Recent studies have identified several subsets of mesenchymal stem cells which exhibit distinct features and biological activities, and enhanced therapeutic potentials for certain diseases. The authors give an overview of these subsets for their phenotypic, biological and functional properties. [Cell Mol Life Sci] Abstract

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.
Sistemic and Cynata Announce Cooperation on In-Process Purity Assay Development for Cell Therapy (CT) Product
Sistemic Ltd. and Cynata Therapeutics Limited announced that they have entered into an agreement which will see Sistemic use its novel SistemQC™ miRNA technology platforms, together with its extensive internal databases of cellular products to develop an in-process assessment assay for Cynata’s unique Cymerus™ CT products. [Sistemic Ltd.] Press Release

Cynata Enters License Option Agreement with apceth GmbH & Co. KG
Cynata Therapeutics Limited announced that it has entered into a worldwide license option agreement with apceth GmbH & Co. KG for the use of Cynata’s unique Cymerus technology in combination with genetic modification technologies designed to open up prospective new therapeutic fields to mesenchymal stem cells, particularly the treatment of cancer. [Cynata Therapeutics Limited (PR Newswire Association LLC)] Press Release

From our sponsor:
Learn about mucociliary differentiation of primary bronchial epithelial cells.
Watch the video.
Nine Years of Censorship
Canadian scientists are now allowed to speak out about their work — and the government policy that had restricted communications. [Nature News] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Symposium on Regenerative Rehabilitation
October 14-16, 2016
Atlanta, United States

Visit our events page to see a complete list of events in the mesenchymal cell community.
NEW Fellowships – Diabetes and Metabolic Associated Disease Research (Pere Virgili Health Research Institute)

NEW Postdoctoral Fellow – Tissue Regeneration (University of Pennsylvania)

NEW Postdoctoral Researcher – Stem Cell Biology, Regenerative Medicine (NUI Galway)

Research Technologist – Mesenchymal Stem Cell Biology (STEMCELL Technologies Inc.)

PhD Student Position – Bone Biology (KU Leuven)

Postdoctoral Position – Craniofacial Molecular Biology (University of Southern California)

Engineering Project Lead (Cytonome)

Postdoctoral Position – Epigenetic Regulation of Cell Fate, Cancer and Metabolism (University Medical Center Freiburg)

Postdoctoral Fellow – Mechanoregulation of Fibrosis and Vascular Injury (St. Michael’s Hospital)

Cell Culture Technician (California Institute of Technology)

Tenure-Track Faculty Positions – Assistant/Associate/Full Professor (Nanyang Technological University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mesenchymal Cell News: Archives | Events | Contact Us